

Supplementary Table 1. The comparison of biochemical tests between the groups and visits

Variable	Screening		Week 24		Change of values (24 weeks–baseline)		
	Value	<i>p</i> value ^a	Values	<i>p</i> value ^a	Difference	<i>p</i> value ^a	<i>p</i> value ^b
AST, IU/L		0.449 ^c		0.193 ^c		0.449 ^c	
Placebo	33 (28–46)		31 (26–40)		–2 (–5 to 4)		0.543 ^d
L-carnitine	38 (27–56)		37 (27–44)		–3 (–16 to 4)		0.014 ^d
ALT, IU/L		0.520 ^c		0.988 ^c		0.520 ^c	
Placebo	24 (18–35)		25 (19–36)		0 (–5 to 3)		0.563 ^d
L-carnitine	26 (20–32)		23 (19–35)		1 (–6 to 6)		0.982 ^d
Albumin, g/dL		0.549 ^c		0.794 ^c		0.243 ^c	
Placebo	4.2 (3.7–4.6)		4.2 (4–4.6)		0.1 (–0.1 to 0.3)		0.084 ^d
L-carnitine	4.4 (3.8–4.7)		4.4 (3.9–4.5)		0 (–0.2 to 0.2)		0.987 ^d
Total bilirubin, mg/dL		0.989 ^c		0.116 ^c		0.003 ^c	
Placebo	1 (0.7–1.6)		1 (0.8–1.5)		0.1 (–0.1 to 0.3)		0.001 ^d
L-carnitine	0.9 (0.8–1.2)		0.9 (0.7–1.2)		0 (–0.2 to 0.1)		0.403 ^d
Prothrombin time, INR		0.647 ^c		0.693 ^c		0.100 ^c	
Placebo	1.2 (1.1–1.2)		1.1 (1.1–1.2)		0 (0 to 0)		0.904 ^d
L-carnitine	1.2 (1.1–1.2)		1.1 (1.1–1.2)		0 (–0.1 to 0)		0.044 ^d
Creatinine, mg/dL		0.799 ^c		0.829 ^c		0.951 ^c	
Placebo	0.8 (0.7–1)		0.8 (0.7–0.9)		0 (–0.1 to 0.1)		0.712 ^d
L-carnitine	0.8 (0.6–0.9)		0.9 (0.7–1)		0 (–0.1 to 0.1)		0.725 ^d
MELD		0.868 ^c		0.409 ^c		0.003 ^c	
Placebo	8 (7–10)		8 (7–11)		0 (0 to 1)		0.047
L-carnitine	8 (7–10)		8 (7–9)		0 (–1 to 0)		0.008
Sodium, mEq/L		0.544 ^c		0.544 ^c		0.867 ^e	
Placebo	140 (138–142)		141 (139–142)		0 (–2 to 2)		0.495 ^f
L-carnitine	140 (138–142)		140 (138–141)		0.5 (–1 to 3)		0.426 ^f
Ammonia, μmol/L		0.567 ^c		0.824 ^c		0.567 ^c	
Placebo	85 (65–118)		74 (57–118)		–8 (–29 to 18)		0.313 ^d
L-carnitine	79 (58–113)		75 (60–96)		–8 (–25 to 9)		0.064 ^d
Total carnitine, μmol/L		0.676 ^c		< 0.0001 ^e		0.676 ^c	
Placebo	67.7 (56.8–73.5)		62.9 (54.4–70.2)		–4.2 (–9.4 to 3)		0.081 ^f
L-carnitine	66.2 (57.9–74.8)		74.9 (66.2–90.2)		10.1 (–5.9 to 19)		0.039 ^f
Acyl carnitine, μmol/L		0.215 ^e		0.046 ^c		0.215 ^e	
Placebo	12.4 (7.1–15.1)		8.5 (6.6–15.1)		–0.8 (–8.4 to 3.3)		0.267 ^f
L-carnitine	13.1 (7.7–18.1)		12 (8.2–20.5)		0.8 (–8.5 to 7.1)		0.779 ^f
Free carnitine, μmol/L		0.953 ^c		< 0.0001 ^e		0.953 ^c	
Placebo	52.8 (45.7–63.4)		50.5 (44.8–59.2)		1.3 (–9.2 to 7.1)		0.660 ^f
L-carnitine	52.5 (45.3–62.3)		65.6 (53.3–78.1)		11.9 (–3.5 to 23)		< 0.001 ^f
LPS, EU/mL		0.527 ^c		0.545 ^c		0.527 ^c	
Placebo	1,000 (365.1–1,000)		1,000 (378.6–1,000)		0 (–138.2 to 196.7)		0.590 ^d
L-carnitine	1,000 (274.6–1,000)		972.3 (310.8–1,000)		0 (–174.4 to 231.2)		0.827 ^d

Values are presented as median (interquartile range).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; LPS, lipopolysaccharides.

^aComparison between the groups.

^bComparison within the groups.

^cWilcoxon's rank sum test.

^dWilcoxon Signed rank test.

^eTwo sample *t* test.

^fPaired *t* test.